Literature DB >> 10577986

Immunomodulation by thalidomide and thalidomide analogues.

L G Corral1, G Kaplan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10577986      PMCID： PMC1766578          DOI： 10.1136/ard.58.2008.i107

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  76 in total

1.  Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis.

Authors:  J M Hanifin; S C Chan; J B Cheng; S J Tofte; W R Henderson; D S Kirby; E S Weiner
Journal:  J Invest Dermatol       Date:  1996-07       Impact factor: 8.551

2.  Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7.

Authors:  A Nakajima; T Kodama; S Morimoto; M Azuma; K Takeda; H Oshima; S Yoshino; H Yagita; K Okumura
Journal:  J Immunol       Date:  1998-08-15       Impact factor: 5.422

Review 3.  Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)

Authors:  R N Maini; M J Elliott; F M Brennan; M Feldmann
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

4.  HIV gp120 inhibits T cell activation by interfering with expression of costimulatory molecules CD40 ligand and CD80 (B71).

Authors:  N Chirmule; T W McCloskey; R Hu; V S Kalyanaraman; S Pahwa
Journal:  J Immunol       Date:  1995-07-15       Impact factor: 5.422

5.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.

Authors:  J L Flynn; M M Goldstein; J Chan; K J Triebold; K Pfeffer; C J Lowenstein; R Schreiber; T W Mak; B R Bloom
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

6.  Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis.

Authors:  J M Tramontana; U Utaipat; A Molloy; P Akarasewi; M Burroughs; S Makonkawkeyoon; B Johnson; J D Klausner; W Rom; G Kaplan
Journal:  Mol Med       Date:  1995-05       Impact factor: 6.354

Review 7.  Thalidomide: rationale for renewed use in immunological disorders.

Authors:  U Schuler; G Ehninger
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

8.  Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.

Authors:  J A Gollob; C P Schnipper; E Orsini; E Murphy; J F Daley; S B Lazo; D A Frank; D Neuberg; J Ritz
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

9.  Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.

Authors:  M W Verghese; R T McConnell; J M Lenhard; L Hamacher; S L Jin
Journal:  Mol Pharmacol       Date:  1995-06       Impact factor: 4.436

10.  The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection.

Authors:  J D Klausner; S Makonkawkeyoon; P Akarasewi; K Nakata; W Kasinrerk; L Corral; R L Dewar; H C Lane; V H Freedman; G Kaplan
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-03-01
View more
  44 in total

1.  Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?

Authors:  J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  The role of angiogenesis in rheumatoid arthritis: recent developments.

Authors:  A E Koch
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 3.  Host-directed therapeutics for tuberculosis: can we harness the host?

Authors:  Thomas R Hawn; Alastair I Matheson; Stephen N Maley; Omar Vandal
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

Review 4.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

5.  Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.

Authors:  Rachid Baz; Mehul Patel; Elizabeth Finley-Oliver; Daniel Lebovic; Mohamad A Hussein; Kena C Miller; Margaret Wood; Taimur Sher; Kelvin Lee; Asher A Chanan-Khan
Journal:  Leuk Lymphoma       Date:  2010-06

6.  Effect of dipyrone and thalidomide alone and in combination on STZ-induced diabetic neuropathic pain.

Authors:  Neha Chauhan; Rajeev Taliyan; Pyare Lal Sharma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-17       Impact factor: 3.000

Review 7.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

8.  Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.

Authors:  Angelo Corti; Monica Giovannini; Carmen Belli; Eugenio Villa
Journal:  J Oncol       Date:  2010-06-03       Impact factor: 4.375

9.  Caloric restriction shortens lifespan through an increase in lipid peroxidation, inflammation and apoptosis in the G93A mouse, an animal model of ALS.

Authors:  Barkha P Patel; Adeel Safdar; Sandeep Raha; Mark A Tarnopolsky; Mazen J Hamadeh
Journal:  PLoS One       Date:  2010-02-24       Impact factor: 3.240

10.  Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus.

Authors:  Lijun Song; Feng Qiu; Yuchen Fan; Feng Ding; Huaxiang Liu; Qiang Shu; Weiwei Liu; Xingfu Li
Journal:  J Clin Immunol       Date:  2012-09-09       Impact factor: 8.317
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.